Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.45 |
| ▸ | CHAT | P28329 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.43 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.42 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | GSR | P00390 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20604275 | 1.00 | TLR8 (0.45) | TLR8CHATSMN1; SMN2HPGDLMNA | |
| SCHEMBL10323297 | 0.89 | CHAT (0.42) | CHATSMN1; SMN2HPGDLMNAALDH1A1 | |
| SCHEMBL3437033 | 0.89 | CHAT (0.42) | CHATSMN1; SMN2HPGDLMNAALDH1A1 | |
| SCHEMBL11652547 | 0.85 | CYSLTR2 (0.47) | CHATSMN1; SMN2HPGDLMNAALDH1A1 | |
| SCHEMBL11652543 | 0.85 | CYSLTR2 (0.47) | CHATSMN1; SMN2HPGDLMNAALDH1A1 | |
| SCHEMBL8206128 | 0.85 | TLR8 (0.51) | TLR8LMNANFE2L2MEN1KMT2A | |
| SCHEMBL28015702 | 0.85 | PTGS2 (0.40) | TLR8SMN1; SMN2LMNAALDH1A1HDAC1 | |
| SCHEMBL29528779 | 0.83 | CHAT (0.47) | CHATSMN1; SMN2HPGDLMNAALDH1A1 | |
| SCHEMBL256666 | 0.83 | CHAT (0.47) | CHATSMN1; SMN2HPGDLMNAALDH1A1 | |
| SCHEMBL6568108 | 0.83 | CHAT (0.47) | CHATSMN1; SMN2HPGDLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3423433-B1 | SULFAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES | BIO PHARM SOLUTIONS CO LTD (KR) | 2025-12-17 | — | — | EP | disclosed |
| CN-109071424-B | Sulfamate derivative compound, preparation method and application thereof | 生物药品解决方案有限公司 | 2022-01-14 | — | — | CN | disclosed |
| US-10351519-B2 | Sulfamate derivative compounds, processes for preparing them and their uses | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2019-07-16 | — | — | US | disclosed |
| US-10351519-B2 | Sulfamate derivative compounds, processes for preparing them and their uses | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2019-07-16 | — | — | US | disclosed |
| EP-3423433-A1 | SULFAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES | Bio-Pharm Solutions Co., Ltd. (KR) | 2019-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351519-B2 | Sulfamate derivative compounds, processes for preparing them and their uses | STS, SULT2A1, SULT1A1 | TLR8 2117/4885CHAT 706/4885SMN1; SMN2 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.